Telomerase inhibitors.
There has been a vast increase in telomerase research over the past several years, with many different pre-clinical approaches being tested for inhibiting the activity of this enzyme as a novel therapeutic modality to treat malignancy. In this review, we will provide some basic background information about telomeres and telomerase and then discuss the pros, cons and challenges of the approaches that are currently under investigation, and what we might expect in the future of this emerging field.
White
L K
LK
Depts of Internal Medicine and Cell Biology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9039, USA.
Wright
W E
WE
Shay
J W
JW
D000818:Animals; D001709:Biotechnology; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D016922:Cellular Senescence; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007167:Immunotherapy; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D016337:RNA, Catalytic / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D019098:Telomerase / Q000037:antagonists & inhibitors*; D016615:Telomere / Q000235:genetics
D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D018894:Reverse Transcriptase Inhibitors; D019098:Telomerase